1. Home
  2. Sistema de Salut de Catalunya
  3. Vall d'Hebron Institut d'Oncologia – VHIO
  4. Articles científics - VHIO
  5. View Item

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Author

Burchert, Andreas

SESQUES, Pierre

Fransecky, Lars

Rejeski, Kai

Barba, Pere

Bücklein, Veit

IACOBONI, GLORIA

Other authors

Institut Català de la Salut

[Rejeski K] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. [Burchert A] Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany. [Iacoboni G, Barba P] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. [Sesques P] Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, Pierre-B enite, France. [Fransecky L] Medical Department II–Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany. [Bücklein V] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-05-24T11:35:19Z

2023-05-24T11:35:19Z

2022-08-23

Share

Abstract

Stem cell; Hematotoxicity; T-cell

Células madre; Hematotoxicidad; Células T

Cèl·lules mare; Hematotoxicitat; Cèl·lules T

This work was supported by a fellowship from School of Oncology of German Cancer Consortium (DKTK) (K.R.) and was funded by the Else Kröner Forschungskolleg; a Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) research grant provided within the Sonderforschungbereich (SFB-TRR 388/1 2021–452881907) and DFG research grant (451580403) (M.S.); the Bavarian Elite Graduate Training Network (M.S.), the Wilhelm-Sander Stiftung (project no. 2018.087.1) (M.S.), the Else-Kröner-Fresenius Stiftung (M.S., K.R., V. Bücklein, V. Blumenberg), and the Bavarian Center for Cancer Research (BZKF).

Document Type

Article

Published version

Language

English

Subjects and keywords

Cèl·lules mare; Estudis de viabilitat; Teràpia cel·lular; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Feasibility Studies; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Salvage Therapy; ANATOMY::Cells::Stem Cells; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios de viabilidad; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento de última línea; ANATOMÍA::células::células madre; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva

Publisher

American Society of Hematology

Related items

Blood Advances;6(16)

https://doi.org/10.1182/bloodadvances.2022007776

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)

Articles científics - HVH [3412]